| | 102625-70-7 Basic information More.. |
| Product Name: | Pantoprazole | | Synonyms: | 5-(DIFLUOROMETHOXY)-2-[[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLE;6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole;PANTOPRAZOLE;PANTOPRAZOLE SODIUM 98-102%;Pantoprazole (base and/or unspecified salts);Pantoprazole&Int.;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-3H-benzoimidazole;(3,4-dimethoxy-2-pyridinyl)methyl 5-methyl-1H-1,3-benzimidazol-2-yl sulfoxide | | CAS: | 102625-70-7 | | MF: | C16H15F2N3O4S | | MW: | 383.37 | | EINECS: | 600-331-6 | | Mol File: | 102625-70-7.mol |  |
Use
Pantoprazole, an irreversible proton pump inhibitor, reached its first market
worldwide in Germany for acute treatment of gastric and duodenal ulcers and
gastroesophageal reflux disease. Proton pump inhibitors are more effective than
other strategies in inhibiting acid secretion since they function at the final step of
acid production, therefore, provide superior symptom relief and healing in all acid
related diseases. As the third substituted benzimidazole proton pump inhibitor
marketed, pantoprazole not only has superior ulcer-preventing effect but also is
more potent than omeprazole in healing acetic acid-induced gastric and duodenal
ulcers with extremely low acute toxicity. The mechanism of action for this class of
compounds has been suggested to be mediated via the protonated form of the
molecule which selectively reacts with cysteines present on the extracytoplasmic
face of the enzyme to form covalent disulfide bonds.
- Pantoprazole
-
- US $0.00-0.00 / kg
- 2025-04-15
- CAS:102625-70-7
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20tons
- Pantoprazole
-
- US $30.00-65.00 / mg
- 2024-11-19
- CAS:102625-70-7
- Min. Order:
- Purity: 99.63%
- Supply Ability: 10g
- Pantoprazole
-
- US $35.00-25.00 / kg
- 2024-03-16
- CAS:102625-70-7
- Min. Order: 1kg
- Purity: 99.8%
- Supply Ability: 200tons/year
|
|
102625-70-7
Recommend Suppliers |
|